Imprimis Pharmaceuticals, Inc. recently filed for registration of its ImprimisRx TX pharmacy — located in Allen, TX — with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility.
According to Imprimis, the Texas facility will make and distribute compounded drugs and will initially distribute the company's proprietary sterile Dropless Therapy® injectable formulations, which are administered following ocular surgery, primarily cataract surgery. This will reportedly allow ophthalmologists the ability to order quantities they need for inventory and office use without providing patient-specific information that is required today. Imprimis expects to begin distributing from the facility towards the end of the second quarter of 2016.
Photo courtesy Imprimis
Click here to read the full press release.
Source: Imprimis Pharmaceuticals, Inc.